The FDA has given the green light for AbbVie's SKYRIZI to be used at home for Crohn's Disease.

Oct 23, 2026, 4:41 PM ETTrialRead the original at prnewswire.com

Good for ABBV

AbbVie's home-start option may make SKYRIZI easier to use and attract more patients. The drug was already approved for Crohn's disease, and added use is only expected, not yet reported.

ABBV · AbbVie Inc.

AI read · Good for ABBV

The AI's read

Home treatment could make SKYRIZI easier for patients to start and help AbbVie reach more patients. The study met its week 12 goals, supporting the new option. SKYRIZI was already approved for Crohn's disease, and wider use is only expected, not yet reported.

Get alerts for ABBV

Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABBV

Free on the App Store and Google Play, or on the web.